inhalation maneuvers using the Respimat SMI. Inspiratory flow rate, inhaled volume, and timing of actuation for each inhalation maneuver were recorded using a pneumotachograph. Successful use and quality of inhalation maneuvers (inspiratory flow rate, theoretical inhaled dose fraction, and estimated lung deposition of the aerosol cloud) were assessed. Results were compared with respect to prior experience of inhaler use and between two age groups (4-8 years and 9-12 years).
Results: Ninety of 99 children achieved one or more successful maneuver. Overall, 75.1 % of inhalation maneuvers performed with the Respimat SMI were successful; the greatest success was seen in older versus younger children. Overall median estimated lung
INTRODUCTION
Inhalation therapy is a cornerstone in the management of chronic respiratory diseases. Direct drug delivery to the lung maximizes therapeutic outcome at the lowest possible dose while minimizing unwanted systemic side effects [1] [2] [3] . Treatment success relies on efficient operation of inhalation devices [4] . For children, achieving effective inhaler use can be challenging because of their different physiological characteristics and comparatively limited coordination [4] .
The Respimat Ò Soft Mist TM inhaler (SMI) is a novel, hand-held, propellant-free, multidose inhalation device that generates a slow-moving, long-lasting aerosol cloud containing a high fine-particle fraction that enables efficient drug delivery to the lungs [5] [6] [7] [8] [9] [10] . For optimal use of the Respimat SMI, the patient is directed to breathe out slowly and deeply. After exhalation the patient is asked to close his or her lips around the end of the mouthpiece [5] . The dose-release button is then pressed while the patient takes a slow, deep inhalation through the mouth; it is recommended that the patient hold this breath in for 10 s [5] . Although the Respimat SMI requires some degree of hand-breath synchronization, it may offer enhanced drug delivery in patients who have difficulties in actuating and coordinating inhalation when using a pressurized metered dose inhaler (MDI) [5] .
A number of studies have shown that patients may find it easier to inhale with the Respimat because of the slow release of the aerosol-approximately 1.5 s, compared with approximately 0.2 s for a chlorofluorocarbon MDI, and 0.3 s for a hydrofluoroalkane MDIand low cloud velocity (\0.8 m/s) with the Respimat [7, 11, 12 ]. However, it is possible that longer spray duration could also lead to a certain ''loss'' of aerosol, if inspiration stops before the end of the aerosol release.
A clinical study confirmed that the design and operative features of the Respimat SMI allows successful use in the pediatric population (children aged 6-15 years) and enabled a twofold reduction in the nominal dose for the treatment of asthma compared with inhalation from an MDI with a spacer [9] . The aim of the current study was to evaluate the use of the Respimat SMI in children aged 4-12 years.
MATERIALS AND METHODS

Study Design
This single-center study was conducted at Mainz University Hospital, Germany, between 
Study Participants
Children aged 4-12 years, of either sex, with asthma bronchiale or atopic diseases, and their healthy siblings were enrolled into the study at the Pediatric Pulmonology and Allergology Outpatient Clinic, Mainz University Hospital.
Children with or without previous inhaler experience were included, and any devices used in the past 12 months were documented.
Children with serious respiratory conditions such as cystic fibrosis or any chronic destructive or severe lung disease were excluded.
Device and Training
A Respimat SMI training kit that delivered an aerosol cloud containing no active medication was used. All children received standardized training on how to achieve a slow and deep inhalation maneuver using the training kit.
During the training, the investigator gave three demonstrations of optimal inhaler technique (or two demonstrations for children aged 9-12 years). Next, the child was allowed three trial inhalations (or two trial inhalations for children aged 9-12 years) during which the investigator gave instructions on how to improve his or her technique, if required.
Training was concluded by a demonstration of the measurement equipment plus one further test inhalation. The children were not given any help using the inhaler from parents or caregivers, and no accessory devices such as spacers were used.
Assessments
Maneuver assessment was based on inhalation flow profiles, recorded using a pneumotachograph (JAEGER 
Statistical Analyses
Median values for the three inhalation quality parameters were recorded for each child who managed one or more successful inhalation maneuver. Statistical analyses were carried out using SPSS (IBM, Armonk, NY, USA [used at University of Mainz]) and SAS (SAS Institute, Inc., Cary, NC, USA [used at Boehringer Ingelheim]). Error rates were calculated for all inhalation maneuvers combined. Differences in the frequency of error rates between groups were analyzed using the Mann-Whitney U test and logistic regression. Differences in quality parameters between groups were analyzed using the Mann-Whitney U test. Linear regression was used for the analyses of dependency of the quality parameters and age.
RESULTS
Study Participants
A total of 99 children were enrolled into the study (n = 59 aged 4-8 years; n = 40 aged 9-12 years). Of these 99 children, 15 had no previous experience with inhalation devices because they had not been diagnosed as having any lung disease, and were hence described as ''healthy.'' Demographics and prior inhaler experience are shown in Table 1 .
Inhalation Success
Overall, 223/297 (75.1 %) of the inhalation maneuvers in 99 children were successful. Of the 74 unsuccessful maneuvers, 14 (18.9 %) were due to more than one type of user error. Actuation error occurred in 33/297 (11. (Fig. 2) . None of the children aged 4 years (n = 3 children, nine maneuvers) were able to perform a successful inhalation, mainly because of coordination problems. In contrast, 5/12 (41.7 %) maneuvers of children aged 5 years (n = 4) and 24/27 (88.9 %) maneuvers of those aged 6 years (n = 9) had successful maneuvers (Appendix Table A1 ).
Inhalation Quality
Overall, 90 of 99 children managed one or more successful inhalation maneuvers and only those children with successful maneuvers were included in the calculation of inhalation quality parameters (inspiratory flow rate, the theoretical inhaled fraction, and the estimated lung deposition). The median estimated lung deposition in this group was 66.9 % (Appendix Fig. A3) . A difference in lung deposition was seen between age groups: children aged 4-8 years (n = 51) achieved a higher median estimated lung deposition (74.2 %) than children aged 9-12 years (n = 39) (61.7 %) (Fig. 3a) . The linear regression shows a linear dependency between age and estimated lung deposition: the older the child, the lower the estimated lung deposition (p\0.01) (Fig. 3b) . Median inspiratory flow rate in all 90 children was 41.5 L/min (range, 7.9-113.5 L/min). Flow rate was [40.0 L/min in 52.2 % of children (Appendix Fig. A4 ).
Inspiratory flow rate was slower in children aged 4-8 years than in the older group (median 30.6 L/min versus 49.9 L/min) (Fig. 4a ). There is a linear trend between age and inspiratory flow: the older the child, the higher the flow (p\0.01) (Fig. 4b) . Total inhaled volumes increased with the age of the children (Appendix Fig. A5 ). 
DISCUSSION
Efficient respiratory drug delivery to the lungs relies on the quality of the inhalation maneuver, which is in turn influenced by device design characteristics. The Respimat SMI generates a slow-moving aerosol cloud that is independent of inspiratory flow rate [7, 13, 14] .
The objective of the current study was to assess the success of inhalation maneuvers and the quality of inhalation breathing patterns among children aged 4-12 years using Respimat SMI; other aspects of device handling were not evaluated. The high percentage of successful inhalation maneuvers (&75 %) in children aged C5 years suggests that these children are able to use the Respimat SMI correctly without adult assistance or breathing aids (e.g., spacer).
Conversely, children aged below 5 years are less able to perform a successful inhalation maneuver with the Respimat SMI; however, information is limited, as only three children aged 4 years were included. These younger children had problems coordinating actuation and inspiration, inhaling slowly and continuously, and holding their breath after inhaling. However, in these children, successful inhalation can be achieved using a spacer and with parental/caregiver help, as appropriate to their age [15] .
In a previous study of children aged 4-14 years using other devices, the rate of correct inhalation maneuvers achieved after training was 88.5 % with the Diskus Ò (GlaxoSmithKline GmbH & Co.
KG, Munich, Germany), 65.4 % with the Turbohaler
Germany), and 42.3 % with the Autohaler [16] . The rate of successful inhalation maneuvers in this study was 75.1 % overall, and 82.5 % in children aged 9-12 years. Although it is necessary to be cautious when comparing across studies, these results suggest that the ease of operating the Respimat SMI compares favorably with the Turbohaler and the Diskus DPI, both of which, unlike the Respimat SMI, require active inspiratory effort to overcome device resistance and achieve adequate drug delivery to the airways. The delivery of drug by the Respimat SMI is independent of inspiratory flow rate and efforts, in contrast to other devices, including
DPIs such as the Turbohaler and the Diskus DPI, which require breath actuation, involving inspiratory effort and a need for a certain flow rate [2, 4, 17, 18] .
In this study, only a small proportion of the errors recorded were device related (i.e., errors in coordinating dose release with inhalation, which occur with all manually operated devices, or exhalation errors caused by coughing in response to inhalation). The rate of device-related errors (11 %) is comparable to that associated with other devices [19] . The rate of inhalation maneuver success with the Respimat SMI was 73 % in children with no prior experience using inhalers, suggesting that those naïve to such devices can operate the Respimat SMI without difficulty. Children naïve recorded in the group of children aged 9-12 years was lower than in those aged 4-8 years. This is explained by higher inspiratory flow rates during inhalation maneuvers in older children, since the higher the inspiratory flow rate, the greater the deposition of drug in the oropharyngeal region rather than in the lungs [13, 20] . Only 48 % of children in the total group inhaled within the optimal flow range of \40 L/ min, and in some children the inhalation flow rate reached beyond 100 L/min. In contrast to the Respimat SMI, DPIs in particular require a high inspiratory flow rate for effective drug delivery and users need to overcome a trigger threshold; children with experience using DPI were, therefore, trained to inhale as quickly and deeply as possible. In the current study, children with experience using DPIs inhaled faster than those without such background.
Although overall maneuver success rates were lowest in the subgroup of children who had previously used spacers, the median inspiratory flow rate from successful inhalations was \40 L/ min, which led to a higher median estimated lung deposition than in children who had used other inhaler devices, and was similar to those without prior inhaler experience. The interpretation of the results from this study is limited by a number of factors, among which are the number of participants and the pneumotachograph, which was added to the inhaler and made handling more difficult. Furthermore, estimated lung deposition was a calculated value and, therefore, only partially comparable with scintigraphic data, and did not take into account device deposition or losses due to re-exhaled aerosol. Pitcairn et al. [8] showed in a scintigraphic study a lung deposition of 51.6 % after an ideal inhalation maneuver. However, the loss due to device deposition and re-exhaled aerosol accounts for the loss of &27 % of the dose, predicting a median estimated lung deposition of 73 % [8] and supporting the plausibility of the results. In this study, a corresponding maneuver (i.e., ideal coordination and inspiratory flow 26 L/min) shows an estimated lung deposition of 83 %, thus somewhat overestimating the results from scintigraphic studies. A strength of this study is that estimated data in children were obtained, which circumvented the need for actual drug deposition scintigraphic studies.
CONCLUSION
These findings demonstrate that children aged 5 years and older can use the Respimat SMI and perform a successful inhalation maneuver;
while children aged 4 years did not meet the success criteria. Children aged 5-8 years achieved higher estimated lung deposition values than children aged 9-12 years, possibly owing to a higher inspiratory flow rate (and, therefore, greater extrathoracic deposition) in the older group.
